Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2026 08:45 ET | Source: F. Hoffmann-La Roche Ltd

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptomsGazyva/Gazyvaro has the...
March 05, 2026 13:45 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value<0.001) while demonstrating placebo-like tolerabilityAt the maximally effective dose, there...
March 02, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with...
February 20, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus...
February 17, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Change to the Roche Enlarged Corporate Executive Committee

Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the appointment of Mark Dawson, M.D., Ph.D., as the new Head of Roche Pharma Research and Early Development (pRED),...
February 16, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years Up to 30% of people with membranous nephropathy progress to...
February 07, 2026 15:40 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in...
January 29, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2025 mit Verkaufswachstum von 7%

Konzernverkäufe stiegen um 7%1 zu konstanten Wechselkursen (CER; 2% in CHF) dank hoher Nachfrage nach Medikamenten und diagnostischen Lösungen.Im vierten Quartal nahm der Umsatz um 8% zu und...
January 29, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive...
January 27, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without...